Destiny Pharma’s collaboration with MedPharm has identified a range of new, stable, XF formulations with promising drug release profiles and scope for the delivery of XF drugs (including clinical stage XF-73, XF-70 and DPD-207 compounds), designed to treat dermal and ocular infections.
These formulations will form the basis of XF drug delivery for the company’s pre-clinical and clinical programmes and treatments for both acute and chronic infections.
Neil Clark,Destiny Pharma’s CEO, commented: “We are pleased to announce positive progress made during 2019 to develop new formulations of XF drugs from our novel antimicrobial XF‐platform. There is an unmet medical need for novel anti-infectives that address dermal and ocular infections with a significantly reduced potential for generating antimicrobial resistance. We look forward to continuing to work with MedPharm to support the expansion of our pipeline as we take select formulations into our ongoing pre‐clinical and clinical studies. Our lead drug candidate from the XF-platform, XF‐73 nasal gel, for the prevention of post‐surgical infections, is currently in Phase 2b development with data expected in mid-2020.”